Avidity Partners Management’s Altimmune ALT Stock Holding History

Avidity Partners Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-105,000	Closed	-$406K	–	44
2025 Q2	$406K	Buy	+105,000	New	+$568K	0.08%	54
2023 Q4	–	Sell	-1,159,900	Closed	-$3.02M	–	75
2023 Q3	$3.02M	Sell	1,159,900 -14,200	-1%	-$40.7K	0.12%	78
2023 Q2	$4.14M	Sell	1,174,100 -141,100	-11%	-$633K	0.14%	84
2023 Q1	$5.55M	Sell	1,315,200 -2,674,800	-67%	-$31.8M	0.18%	71
2022 Q4	$65.6M	Buy	3,990,000 +1,306,000	+49%	+$14.7M	1.42%	26
2022 Q3	$34.3M	Sell	2,684,000 -297,000	-10%	-$4.39M	0.7%	45
2022 Q2	$34.9M	Buy	2,981,000 +116,000	+4%	+$715K	0.8%	33
2022 Q1	$17.4M	Buy	2,865,000 +100,000	+4%	+$736K	0.36%	56
2021 Q4	$25.3M	Buy	2,765,000 +597,100	+28%	+$6.34M	0.54%	51
2021 Q3	$24.5M	Buy	+2,167,900	New	+$26.4M	0.54%	51

Other funds holding ALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Avidity Partners Management's ALT Position: Q3 2025 in Review

Avidity Partners Management sold out of Altimmune (ALT) in Q3 2025, closing a stake of 105,000 shares — an estimated $406K sold.

Avidity Partners Management first reported a position in ALT in Q3 2021 and held it in 10 quarters. The position peaked at $65.6M in Q4 2022. 158 funds tracked by Wall St. Rank hold ALT as of Q3 2025.

Avidity Partners Management reported no remaining Altimmune position as of Q3 2025 after selling out during the quarter.
Avidity Partners Management sold 105,000 Altimmune shares in Q3 2025, an estimated $406K.
Avidity Partners Management first reported a position in Altimmune in Q3 2021 and held it in 10 quarters.
Avidity Partners Management's Altimmune position peaked at $65.6M in Q4 2022.
158 funds tracked by Wall St. Rank held Altimmune as of Q3 2025.

Based on Avidity Partners Management's 13F filing for Q3 2025, filed 14 Nov 2025.